CalculatorHaematology
EUTOS score in chronic myeloid leukaemia
Predicts the probability of not reaching complete cytogenetic response at 18 months on imatinib in chronic-phase CML.
Updated 31 October 2026
When to use it
Patients with chronic-phase CML at diagnosis, before starting a tyrosine kinase inhibitor.
What it needs
- Peripheral blood basophils
- Palpable spleen below the costal margin
Formula
EUTOS = 7 × basophils (%) + 4 × spleen (cm below costal margin)
High risk if > 87
How to interpret it
The result is read in its clinical context; the app shows it with its units and warnings.
In the app it also calculates: Risk group.
Practical tip
Use pre-treatment data only: it is not valid in already treated patients.
2 more practical tips in the app.
Reference
- Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118(3):686-692.
- Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966-984.
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
